CuraTeQ Biologics Receives Marketing Authorization from CDSCO for Bevacizumab Biosimilar Bevqolva®
Aurobindo Pharma Limited has announced that its wholly owned subsidiary, CuraTeQ Biologics Private Limited, has received Marketing Authorization from the Central Drugs Standard Control Organization (CDSCO). The authorization pertains to Bevqolva®, a bevacizumab biosimilar.The Marketing Authorisation, granted under Form CT 23, indicates that Bevqolva® is designed for the treatment of metastatic carcinoma of the colon or rectum.
The clearance allows for the manufacture of the product at CuraTeQ’s facility located in Hyderabad. Furthermore, the authorization permits the marketing of Bevqolva® in two specified presentations: 100 mg/4mL and 400 mg/16 mL vial presentations.
AUROPHARMA Stock Price Movement
On Friday, Aurobindo Pharma Limited shares slipped by 0.04% to settle at ₹1511.8, marking a slight retreat after hitting its 52-week high of ₹1528. Despite the dip, the stock found support during the session, posting a solid traded volume of 707,047 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.